News | November 06, 2025
Teva reports 11th consecutive quarter of growth
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma
RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options
Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development
Milestone also announced the extension of its $75 million Royalty Purchase Agreement with RTW Investments
The trial targets MCAS/MCAD, an under-recognized, debilitating condition with an unknown cause and no cure
Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide
GL0034 administered once-weekly confirmed clinically meaningful weight loss and improved glucometabolic parameters over a 4-week treatment period in individuals with obesity
Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
Subscribe To Our Newsletter & Stay Updated
